Literature DB >> 28487033

Incidence and Long-Term Clinical Impact of Late-Acquired Stent Fracture After Sirolimus-Eluting Stent Implantation in Narrowed Coronary Arteries.

Shoichi Kuramitsu1, Hiroyuki Jinnouchi2, Tomohiro Shinozaki3, Takashi Hiromasa2, Yukiko Matsumura2, Yuhei Yamaji2, Mizuki Miura2, Hiroaki Matsuda4, Hisaki Masuda2, Takenori Domei2, Yoshimitsu Soga2, Makoto Hyodo2, Shinichi Shirai2, Kenji Ando2.   

Abstract

The incidence and long-term clinical impact of stent fracture (SF) occurred beyond 1 year after sirolimus-eluting stent (SES) implantation remains unclear. From April 2004 to March 2008, 985 consecutive patients with 1,307 lesions were treated only with SES. Of these, 868 patients (88.1%) with 1,140 lesions underwent follow-up angiography within 1 year after the index procedure, and 646 patients (65.6%) with 872 lesions underwent it both within and beyond 1 year after the index procedure. According to the diagnosed timing of SF, we divided the patients into the 2 groups: early SF (<1 year after the index procedure) and late-acquired SF (>1 year after the index procedure). Early- and late-acquired SFs were observed in 64 of 868 patients (7.4%) and 66 of 1,140 lesions (5.8%); 12 of 646 patients (1.9%) and 12 of 872 lesions (1.4%), respectively. Cumulative 10-year incidence of clinically driven target lesion revascularization and definite stent thrombosis were numerically higher in the early- and late-acquired SF groups than in the non-SF group (41.6% vs 45.5% vs 19.0%; 8.0% vs 8.3% vs 2.0%, respectively). In conclusion, late-acquired SF after SES implantation occurred in 1.4% of lesions, which was lower than that of early SF. However, both early- and late-acquired SFs appeared to be associated with clinically driven target lesion revascularization and stent thrombosis during the long-term follow-up.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28487033     DOI: 10.1016/j.amjcard.2017.03.259

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Characterizing fretting damage in different test media for cardiovascular device durability testing.

Authors:  J D Weaver; L Ramirez; S Sivan; M Di Prima
Journal:  J Mech Behav Biomed Mater       Date:  2018-04-04

Review 2.  Drug-eluting stent thrombosis: current and future perspectives.

Authors:  Shoichi Kuramitsu; Shinjo Sonoda; Kenji Ando; Hiromasa Otake; Masahiro Natsuaki; Reo Anai; Yasuhiro Honda; Kazushige Kadota; Yoshio Kobayashi; Takeshi Kimura
Journal:  Cardiovasc Interv Ther       Date:  2021-01-13

3.  Intravascular Ultrasound-Guided Treatment for In-stent Restenosis Associated with Stent Fracture in Overlapped Drug-eluting Stents.

Authors:  Min Chul Kim; Myung Ho Jeong; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn
Journal:  Chonnam Med J       Date:  2019-09-24

4.  Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.

Authors:  Gregg W Stone; Takeshi Kimura; Runlin Gao; Dean J Kereiakes; Stephen G Ellis; Yoshinobu Onuma; Bernard Chevalier; Charles Simonton; Ovidiu Dressler; Aaron Crowley; Ziad A Ali; Patrick W Serruys
Journal:  JAMA Cardiol       Date:  2019-12-01       Impact factor: 14.676

5.  Design and Analysis of a Biodegradable Polycaprolactone Flow Diverting Stent for Brain Aneurysms.

Authors:  Kaitlyn Tidwell; Seth Harriet; Vishal Barot; Andrew Bauer; Melville B Vaughan; Mohammad R Hossan
Journal:  Bioengineering (Basel)       Date:  2021-11-12

6.  Incidence of coronary drug-eluting stent fracture: A systematic review and meta-analysis.

Authors:  Yang Chen; Dandan Li; Yanhui Liao; Xiongda Yao; Yuehua Ruan; Kai Zou; Hanhui Liao; Jingwen Ding; Hao Qin; Zuozhong Yu; Yuanbin Zhao; Longlong Hu; Renqiang Yang
Journal:  Front Cardiovasc Med       Date:  2022-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.